Skip to main content
Top
Published in: World Journal of Urology 9/2021

01-09-2021 | COVID-19 | Topic Paper

Clinical trials in urological oncology: COVID-19 and the potential need for a new perspective

Authors: Jiasian Teh, Ellen O’Connor, Jasamine Coles-Black, Nathan Lawrentschuk

Published in: World Journal of Urology | Issue 9/2021

Login to get access

Abstract

The COVID-19 pandemic has led to the suspension, termination or alteration of thousands of clinical trials as the health emergency escalated globally. Whilst the rapid suspension of certain clinical trials was necessary to ensure the safety of high-risk or vulnerable trial participants as well as healthcare workers, the long-term ramifications that this delay will have on the field of urologic oncology is unknown. The COVID-19 pandemic has highlighted the need to plan for and implement new strategies to advance our understanding of unmet areas of need in urologic oncology. The COVID-19 pandemic has led to the suspension, termination or alteration of thousands of clinical trials as the health emergency escalated globally. Whilst the rapid suspension of certain clinical trials was necessary to ensure the safety of high-risk or vulnerable trial participants as well as healthcare workers, the long-term ramifications that this delay will have on the field of urologic oncology is unknown. The COVID-19 pandemic has highlighted the need to plan for and implement new strategies to advance our understanding of unmet areas of need in urologic oncology.
Literature
3.
go back to reference Gostin LO, Friedman EA, Wetter SA (2020) Responding to Covid-19: how to navigate a public health emergency legally and ethically. Hastings Cent Rep 50(2):8–12CrossRef Gostin LO, Friedman EA, Wetter SA (2020) Responding to Covid-19: how to navigate a public health emergency legally and ethically. Hastings Cent Rep 50(2):8–12CrossRef
4.
go back to reference Parmar MKB, Barthel FMS, Sydes M, Langley R, Kaplan R, Eisenhauer E et al (2008) Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 100(17):1204–1214CrossRef Parmar MKB, Barthel FMS, Sydes M, Langley R, Kaplan R, Eisenhauer E et al (2008) Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 100(17):1204–1214CrossRef
6.
go back to reference Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9(1):34CrossRef Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9(1):34CrossRef
7.
go back to reference Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409CrossRef Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409CrossRef
Metadata
Title
Clinical trials in urological oncology: COVID-19 and the potential need for a new perspective
Authors
Jiasian Teh
Ellen O’Connor
Jasamine Coles-Black
Nathan Lawrentschuk
Publication date
01-09-2021
Publisher
Springer Berlin Heidelberg
Keyword
COVID-19
Published in
World Journal of Urology / Issue 9/2021
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-020-03416-4

Other articles of this Issue 9/2021

World Journal of Urology 9/2021 Go to the issue